<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gonadorelin acetate (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gonadorelin acetate (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Gonadorelin acetate (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="15999" href="/d/html/15999.html" rel="external">see "Gonadorelin acetate (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52867070"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Lutrepulse</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F177075"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Gonadotropin</li></ul></div>
<div class="block doa drugH1Div" id="F177042"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1183e318-e26f-41b8-a7ef-7a8dc176b4cc">Primary hypothalamic amenorrhea</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Primary hypothalamic amenorrhea:</b> Females: IV, SubQ.: Initial dose: 5 mcg every 90 minutes via suitable pulsatile pump. Dosage adjustments may be made every 21 days if necessary. An increase in dosage may be necessary if no response after 3 treatment intervals. In clinical trials, doses of 1-20 mcg were successfully administered. Treatment should be continued for 2 weeks after ovulation to maintain the corpus luteum.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Appropriate vial should be selected for individualized treatment. Typical dose (5 mcg) is delivered with use of 0.8 mg vial.</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F177015"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Superficial thrombophlebitis</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Injection site irritation</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abdominal pain, anaphylactic shock, anaphylaxis, antibody development (with long-term therapy, resulting in therapy failure), erythema at injection site, fever, headache, hypermenorrhea, inflammation at injection site (mild and severe), nausea, ovarian hyperstimulation syndrome (moderate)</p></div>
<div class="block coi drugH1Div" id="F177028"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to gonadorelin or any component of the formulation; women with any condition (eg, pituitary prolactinoma) that could be exacerbated by pregnancy; patients who have ovarian cysts; any condition (eg, hormone-dependent tumor) that may be worsened by reproductive hormones </p></div>
<div class="block war drugH1Div" id="F177013"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity/anaphylactic reactions: Hypersensitivity and anaphylactic reactions have been reported rarely.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ovarian cancer: <b>[Canadian Boxed Warning]: Ovarian cancer has been reported in a very small number of infertile women treated with fertility drugs. A causal relationship has not been established.</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Ovarian hyperstimulation syndrome: <b>[Canadian Boxed Warning]: Ovarian hyperstimulation syndrome (OHSS) is a risk of ovulation induction therapy although it is rare with pulsatile gonadotropin releasing hormone (GnRH) therapy. Discontinue therapy if OHSS occurs; spontaneous resolution may be expected.</b> OHSS is a rare exaggerated response to ovulation induction therapy (Corbett 2014; Fiedler 2012). This syndrome may begin within 24 hours of treatment but may become most severe 7 to 10 days after therapy (Corbett 2014). Symptoms of mild/moderate OHSS may include abdominal distention/discomfort, diarrhea, nausea, and/or vomiting. Severe OHSS symptoms may include severe abdominal pain, anuria/oliguria, ascites, severe dyspnea, hypotension, or nausea/vomiting (intractable). Decreased creatinine clearance, hemoconcentration, hypoproteinemia, elevated liver enzymes, elevated WBC, and electrolyte imbalances may also be present (ASRM 2016; Corbett 2014; Fiedler 2012). Treatment is primarily symptomatic and includes fluid and electrolyte management, analgesics, and prevention of thromboembolic complications (ASRM 2016; SOGC-CFAS 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Experienced physician: Therapy should only be conducted by clinicians familiar with infertility problems and their management.</p>
<p style="text-indent:-2em;margin-left:4em;">• Multiple births: May result from the use of these medications; advise patients of the potential risk of multiple births before starting treatment.</p></div>
<div class="block prod-avail drugH1Div" id="F11300326"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the US</p></div>
<div class="block geq drugH1Div" id="F53040726"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block dinfoc drugH1Div" id="F52867071"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lutrepulse: 0.8 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F177025"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV, SubQ: Lutrepulse vials for IV or SubQ use: Following reconstitution, administer IV or SubQ using a suitable pulsatile pump. Set the pump to deliver 25 or 50 mcL of solution, based upon the dose required and vial strength used. When using the 0.8 mg vial, the pump can be set to deliver a dose of 2.5 mcg (25 mcL) per pulse or 5 mcg (50 mcL) per pulse. When using the 3.2 mg vial, the pump can be set to deliver a dose of 10 mcg (25 mcL) per pulse or 20 mcg (50 mcL) per pulse. Pump should deliver dose over a pulse period of 1 minute and a pulse frequency of 90 minutes.</p></div>
<div class="block use drugH1Div" id="F177024"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not approved in the US</p>
<p style="text-indent:-2em;margin-left:2em;">Induction of ovulation in females with hypothalamic amenorrhea</p></div>
<div class="block mst drugH1Div" id="F26116839"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">
<b>ALERT: Canadian Boxed Warning:</b> Health Canada-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299419"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F177017"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F11300324"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">The risk of fetal harm appears remote if gonadorelin is used during pregnancy. Clinical studies of pregnant women have not demonstrated an increased risk of fetal abnormalities during the first trimester. Follow-up reports of infants born to exposed mothers revealed no adverse effects or complications attributed to gonadorelin therapy. Based on its indicated use, gonadorelin treatment is continued for 2 weeks following ovulation to maintain the corpus luteum; initiation of treatment is not appropriate if pregnancy has been established.</p></div>
<div class="block brc drugH1Div" id="F11300325"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if gonadorelin is excreted into breast milk. Not indicated for use in nursing women.</p></div>
<div class="block mop drugH1Div" id="F177021"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Ovarian ultrasound at baseline and at least weekly while on therapy or until ovulation is confirmed; LH, FSH, estradiol, progesterone (midluteal phase); basal body temperature; pelvic exam; injection site</p>
<p style="text-indent:-2em;margin-left:2em;">OHSS: Monitoring of hospitalized patients should include abdominal circumference, albumin, cardiorespiratory status, electrolytes, fluid balance, hematocrit, hemoglobin, serum creatinine, urine output, urine specific gravity, vital signs, weight (all daily or as necessary) and liver enzymes (weekly) (SOGC-CFAS 2011)</p></div>
<div class="block pha drugH1Div" id="F177012"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Stimulates the release of luteinizing hormone (LH) from the anterior pituitary gland</p></div>
<div class="block phk drugH1Div" id="F177027"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Response to therapy usually observed within 2-3 weeks</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: ~10-15 L</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Primarily renal </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Terminal: ~10-40 minutes; increased in patients with renal impairment</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (as inactive metabolites)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038649"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Lhrh</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Relefact lh-rh</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Relisorm l</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Lutrelef</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Lhrh | Relisorm l</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Lhrh | Relefact lh-rh</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Relefact lh rh</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Luforan</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Lhrh ferring | Relefact lh rh</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Fertiral | Hrf | Relefact lh rh</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Lutrelef</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Lutamin | Relisorm</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Relefact lh-rh</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Hrf | Lutrelef | Relefact lh-rh</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Lhrh ferring</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Lutrelef | Relefact lh rh | Relisorm l</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Factrel</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Relefact lh-rh | Relisorm</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Relisorm l</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Relisorm-l</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Relefact lh-rh</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-25574681">
<a name="25574681"></a>Corbett S, Shmorgun D, Claman P, et al; Reproductive Endocrinology Infertility Committee. The prevention of ovarian hyperstimulation syndrome. <i>J Obstet Gynaecol Can</i>. 2014;36(11):1024-1033. doi: 10.1016/S1701-2163(15)30417-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gonadorelin-acetate-united-states-not-available-drug-information/abstract-text/25574681/pubmed" id="25574681" target="_blank">25574681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22531097">
<a name="22531097"></a>Fiedler K, Ezcurra D. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. <i>Reprod Biol Endocrinol</i>. 2012;10:32. doi: 10.1186/1477-7827-10-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gonadorelin-acetate-united-states-not-available-drug-information/abstract-text/22531097/pubmed" id="22531097" target="_blank">22531097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22416285">
<a name="22416285"></a>Joint Society of Obstetricians and Gynaecologists of Canada-Canadian Fertility and Andrology Society (SOGC-CFAS) Clinical Practice Guidelines Committee, Shmorgun D, Claman P, Gysler M, et al. The diagnosis and management of ovarian hyperstimulation syndrome: No. 268, November 2011. <i>Int J Gynaecol Obstet</i>. 2012;116(3):268-273.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gonadorelin-acetate-united-states-not-available-drug-information/abstract-text/22416285/pubmed" id="22416285" target="_blank">22416285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11209627">
<a name="11209627"></a>Kesrouani A, Abdallah MA, Attieh E, Abboud J, Atallah D, Makhoul C. Gonadotropin-releasing hormone for infertility in women with primary hypothalamic amenorrhea. Toward a more-interventional approach. <i>J Reprod Med</i>. 2001;46(1):23-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gonadorelin-acetate-united-states-not-available-drug-information/abstract-text/11209627/pubmed" id="11209627" target="_blank">11209627</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Lutrepulse (gonadorelin acetate) [product monograph]. North York, Ontario, Canada: Ferring Inc; August 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27678032">
<a name="27678032"></a>Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. <i>Fertil Steril</i>. 2016;106(7):1634-1647. doi: 10.1016/j.fertnstert.2016.08.048.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gonadorelin-acetate-united-states-not-available-drug-information/abstract-text/27678032/pubmed" id="27678032" target="_blank">27678032</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 15998 Version 90.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
